‘Game-changing’ Alzheimer’s drug that ‘slows decline by 60%’ is approved in US – as UK decision expected within months
A “GAME-CHANGING” Alzheimer’s drug that slows mental decline by up to 60 per cent has been approved in the United States.
Donanemab, known commercially as Kisunla, will be available for patients with early symptoms of the disease.
APIn Alzheimer’s disease, two proteins build up which causes brain cells to die[/caption]The medicine remains under consideration by Britain’s regulator, the Medicines and Healthcare products Regulatory Agency (MHRA).
A decision is expected in the coming months.
Заголовки